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Introduction: Hypofractionated stereotactic body radiotherapy
(SBRT) is an emerging noninvasive technique for the treatment of
oligometastatic cancer. The use of small numbers of large doses, should
in theory, achieve high rates of local control. The aim of this literature
review is to critically assess the use of SBRT for the treatment of
pulmonary metastases as judged by its effect on local control, survival,
and toxicity.
Methods: A systematic literature search was performed. Both single
fraction stereotactic radiosurgery (SRS) and hypofractionated radiother-
apy (SBRT) were considered individually. Thirteen institutions re-
ported results regarding SBRT and seven institutions regarding SRS (a
total of 29 publications). Outcomes, techniques, radiobiology, and the
scientific rigor of the reported studies were analyzed.
Results: A wide range of techniques, doses, and dose fractionation
schedules were found. Three hundred thirty-four patients with 564
targets were reported in the SBRT series. The 2-year weighted local
control was 77.9%. The corresponding 2-year weighted overall survival
was 53.7%, with a 4% rate of grade 3 or higher radiation toxicities. One
hundred fifty-four patients with 174 targets were treated in the SRS
series. The 2-year weighted local control was 78.6%. The correspond-
ing weighted 2-year overall survival was 50.3%, with 2.6% rate of
grade 3 or higher toxicities.
Conclusion: There was insufficient evidence to recommend a consen-
sus view for optimal tumor parameters, dose fractionation, and techni-
cal delivery of treatment. This indicates the need for further prospective
studies. However, high local control rates that could potentially lead to
a survival benefit justifies the consideration of stereotactic radiotherapy
for patients with limited pulmonary oligometastases.
Key Words: Stereotactic, Radiotherapy, Radiosurgery, Metastases,
Lung.
(J Thorac Oncol. 2010;5: 1091–1099)
The management of patients with distant metastasis fromsolid tumors is usually conducted with palliative intent, with
rare exceptions. Treatment predominantly involves the use of
systemic chemotherapy, with targeted radiotherapy or other
local measures typically reserved for symptom relief.1 Chemo-
therapy is delivered without expectation of long-term survival.
Observing the natural history of breast cancer, Hellman and
Weichselbaum2 hypothesized the existence of a state intermedi-
ate between widespread metastatic disease and locally confined
disease and coined the term “oligometastasis.” In this setting, the
role of potentially ablative local targeted therapies has been
investigated either with curative intent in the assumption that
oligometastases are the only remaining burden of disease or in
the hope that reduction of tumor burden will increase the
effectiveness of subsequent chemotherapy (Norton-Smith hy-
pothesis3). Metastasectomy has been shown to increase median
survival in patients with single brain metastases from 15 to 40
weeks (p  0.01).4 Systematic reviews of the resection of
hepatic metastases show a median 5-year survival of 25 to
30%.5,6 Similarly, a systematic review of adrenalectomy for
metastases showed a median 5-year survival of 25%.7 Surgical
resection of pulmonary metastases is also becoming increasingly
prevalent.
Pulmonary parenchymal tissue represents a common site
for metastatic seeding. Sarcoma and epithelial malignancies (in
particular colorectal cancers) have a particular tendency toward
metastasis to the lung. In the International Registry of Lung
Metastases, 5206 cases of lung metastasectomy were recorded.
Resected tumors were epithelial in 43%, sarcomatoid in 42%,
germ cell in 7%, and malignant melanoma in 6%, respectively.
An overall 5-year overall survival rate of 36% was reported in
completely resected cases,8 with a 15-year survival of 22%. The
median survival was 35 months. These results are remarkably
good, given the typically poor survival for patients with meta-
static solid tumors.
More recently, less invasive techniques have been used to
treat oligometastatic lung disease. These include radiofrequency
ablation and stereotactic radiotherapy and are especially attrac-
tive approaches in patients who refuse or are unsuitable for
surgery. “Radiosurgery” was a term first coined by Swedish
neurosurgeon Lars Leksell in the 1950 to describe single-dose
ablative radiotherapy delivered to brain lesions through ster-
eotaxy.9 The term stereotaxis applies to the realization of tumor
position via the use of coordinates derived from external surro-
gate markers or fiducials. These fiducials allow the determina-
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tion of tumor coordinates in the sagittal, coronal, and axial
planes. This principle has been extrapolated to the stereotactic
delivery of hypofractionated treatments for pulmonary metasta-
ses. Lax et al.10 developed the first stereotactic body frame to
enclose the body from head to midfemoral region with vacuum
stabilization to provide high surface contact (Figure 1). Both
single fraction radiosurgery and hypofractionated pulmonary
radiotherapy have been reported using stereotactic techniques.
THE BASIC PRINCIPLES OF STEREOTACTIC
TREATMENT
Stereotactic techniques are usually combined with hypo-
fractionation, defined as the delivery of a small number of large
doses of radiation. This is a major departure from the typical
fractionation of standard radiotherapy delivered with curative
intent to epithelial tumors, which generally involves the use of
30 or more small doses, (1.8–2 Gy per fraction) delivered 5 days
per week. Recent work with hypofractionation for pulmonary
malignancies has resulted in the use of fractions up to 30 Gy
delivered in an accelerated fashion over 1 to 3 weeks.11–13 The
very large hypofractionated doses used in stereotactic body
radiotherapy (SBRT) can be given safely because (a) the treated
volumes are small with tight margins and (b) the technique
employs a large number of beams (eight or more), which
individually contribute a small dose along their path but together
result in a much larger dose where they intersect and are
summed at the locus of the cancer (Figures 2 and 3).
The linear quadratic (LQ) equation14 is often used to
estimate cell survival to radiation. The LQ equation is used to
calculate biologic equivalent doses (BEDs) between the various
fractionation schemes reported below, because this allows a
direct comparison of effective doses for early effects to tumor
and normal tissues. However, at very large doses per fraction,
radiotherapy becomes tissue ablative, and the LQ equation may
underestimate the effect,15 therefore the absolute values of the
BED calculations should be interpreted with caution.
The term “radiosurgery” to describe single fraction abla-
tive radiotherapy is misleading, as it does not involve surgery at
all. It could be argued that it is an anachronism that should be
consigned to history, and that radioablation is a more appropriate
term. Similarly, the definition of stereotaxis has been somewhat
loosely applied throughout the literature. The need for stereo-
tactic methods for precise tumor localization has been largely
replaced by image-guided radiotherapy, although the term “ste-
reotactic” is still often used. Image-guided radiotherapy involves
the use of some method of radiologic localization of the tumor
in the treatment room immediately before or during treatment
delivery. This may be with volumetric soft tissue imaging
devices attached to the treatment machine (for example cone
beam computed tomography [CT]), or with implanted radio-
opaque fiducials that are detectable by orthogonal kilovoltage
x-rays. In this review of the literature, we will consider all
FIGURE 1. Stereotactic body frame and vacuum immobiliza-
tion, with abdominal compression, Peter MacCallum Centre.
FIGURE 2. Axial computed tomography dose color wash
and beam arrangement, Peter MacCallum Cancer Centre.
FIGURE 3. Three-dimensional reconstruction of noncoplanar
beam arrangement around target (cyan), Peter MacCallum
Cancer Centre.
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definitions of stereotactic radiotherapy and radiosurgery pub-
lished to date. A large proportion of published reports regarding
stereotactic hypofractionated radiotherapy address treatment of
both primary non-small cell lung cancer (NSCLC) and meta-
static pulmonary lesions. This review will focus only on the
reported outcomes of those patients treated for metastatic dis-
ease.
MATERIALS AND METHODS
A literature search was performed using Medline for the
period from 1990 to April 2009. The search was limited to
articles in English print and employed the following terms;
“stereotactic AND radiotherapy OR Radiosurgery NOT cerebral
NOT brain” was combined with “lung OR pulmonary OR
thoracic” and “metastases OR metastatic OR oligometastases.”
This yielded 115 publications. Where multiple publications
existed for a single institution, outcome data from only the most
recent or most relevant articles were included. However, previ-
ously published information regarding treatment techniques
could be considered if this gave useful additional information.
Several groups published articles that reported data on the
treatment of both pulmonary metastases and primary lung can-
cers in the same article. In such cases, only data relevant to
metastases were considered. In total, 13 institutions reported on
stereotactic fractionated radiotherapy, and seven institutions re-
ported on single fraction stereotactic radiosurgery. Relevant
information concerning tumor characteristics, treatment tech-
niques, duration of follow-up, treatment-related toxicities, and
radiobiological information is shown in Table 1. Two-year
overall survival and local control data, when not reported, were
extrapolated from reported time points assuming a constant
hazard. Weighted mean 2-year local control rate, BED, and
2-year overall survival have been calculated using the average of
each of the categories with respect to the contribution of the
number of patients within each dataset.
SINGLE FRACTION RADIOABLATION
In total, there were six institutions reporting single fraction
stereotactic “radiosurgery” for thoracic metastases. These insti-
tutions are tabulated in chronological order of publication, from
2000 to 2007 (Table 1). This experience encompasses 148
patients with 175 targets, which highlights the paucity of data
available for this technique. Only Fritz’s and Hof’s groups
analyzed their data prospectively, collectively treating 86
patients. Hara et al., Le et al., and Hof et al. have all
performed phase I dose escalation studies. There are no
reported randomized phase III studies of single fraction
stereotactic radioablation.
Five of the six groups treated both central and peripheral
tumors. Three of these six groups prescribed a lower dose to
centrally located tumors. The justification for treating central
tumors with more caution can be extrapolated from the stereo-
tactic experience in NSCLC. Timmerman et al.21 reported a
2-year freedom from severe toxicity for peripheral tumors of
TABLE 1. Reference(s), Patient/Target Population, and Tumor Characteristics
Author(s)
Patients/
Targets
Target Size, Median
(Range)
Eligible
Locations
Number of
Synchronous
Metastases
Primary/Histology
(%)
Phase I
Data? Motion Management
Nakagawa
et al.16
14/21 Median 40 ml (5–126 ml) Central/peripheral 1 36% liver, 21% lung,
14% colon, 14%
thymoma, 7%
esophagus, 7%
myeloma
No Megavoltage CT pretreatment
planning CT and treatment
with shallow breathing
Hara et al.17 11/15 40 mm, median 4 ml
(1–16 ml)
Central/peripheral Not specified 36% lung, 27% liver,
18% H & N, 9%
cervix, 9% breast,
9% bladder
Yes End expiratory and max
inspiratory phases for
planning CT, pretreatment
CT, respiratory-gated
treatment and custom bed
for immobilization
Wulf et al.18 25/25 25 ml Central/peripheral 1 to 2 45% lung, 10%
breast, 8% colon,
8% kidney, 8%
sarcoma, 6% HCC,
12% others
No 4D planning CT, pretreatment
CT and stereotactic body
frame
Le et al.11 12/12 Mean 26 ml, median
27 ml
Central/peripheral 1 to 2 63% AdenoCa, 22%
SCC, 6% NSCLC,
6% sarcoma, 3%
HCC
Yes 4D planning x-rays, orthogonal
x-rays  respiratory
tracking via CyberKnife,
vacuum immobilization
Fritz et al.19 25/31 CTV, median 6 ml
(2.8–55.8 ml)
Peripheral only 1 to 2 32% lung, 29%
rectal, 19% breast,
10% H & N, 10%
other
No Three phase CT planning three
phase pretreatment CT
Stereotactic body frame
Hof et al.20 61/71 Median 10 ml (1–53 ml) Central/peripheral 1 to 2 51% lung, 13%
colorectal, 6%
breast, 30% other
Yes Fluoroscopy, dynamic 4D
planning CT, stereotactic
body frame  abdominal
compression
CT, computed tomography; NSCLC, non-small cell lung cancer.
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83%, compared with only 54% for central tumors (p  0.004).
Although there were no grade 5 toxicities reported in the oligo-
metastatic patients of Le et al.,11 there were three in the corre-
sponding NSCLC cohort, all to central targets. Two of these
deaths occurred after initiation of adjuvant gemcitabine chemo-
therapy. Larger tumor size was also predictive of severe toxicity.
There was considerable variation in target size treated
throughout the groups. In the largest reported study of 61
patients, the median volume was small at only 10 cm3. Four of
the six institutions allowed up to two synchronous metastases to
be treated. All of the institutions used some method of motion
management at planning and/or treatment. Four of the six
institutions reported the use of an immobilization device. Three
of six used a stereotactic body frame. Le et al. reported results
with the use of a CyberKnife (Accuray, Sunnyvale, CA) while
all other groups used a gantry operated linear accelerator.
The median follow-up reported among the groups ranged
from 9 to 22 months. There were few toxicities reported (Table
2). There were five grade 3 toxicities reported and no grade 4 or
5 toxicities reported among the institutions. Crude local control
varied markedly among the groups. The BED in 2 Gy fractions
using an / ratio of 10 were reported in four of the seven
groups. The BED could be calculated in a further two studies.
The mean weighted 2-year local control rate was 78.6% (range,
48–91%). The weighted 2-year overall survival was 50.3%
(range, 33–73%). Of those reported, the mean weighted BED at
the periphery was 87.1 Gy.
HYPOFRACTIONATED RADIOTHERAPY
There are 13 institutions that have reported experience
with stereotactic fractionated body radiotherapy, tabulated in
chronological order of publication (Table 3). This corresponds to
a considerably larger reported experience than single fraction
radioablation for pulmonary oligometastases, with a total of 334
patients and 564 targets. In total, five institutions prospectively
enrolled data, with the most robust data being published by
Rusthoven et al.38 with a multi-institutional phase II trial. Three
of 13 institutions completed a phase I dose escalation study
before selecting a fractionation schedule. Again, there are no
phase III randomized trials of fractionated stereotactic radiother-
apy. Target sizes varied considerably between institutions. Two
of 13 institutions excluded central targets, whereas one group
treated central targets with an altered fractionation. The majority
of institutions limited treatment for three or less synchronous
pulmonary metastases. One group treated between one and five
synchronous targets, inclusion criteria that test the concept of the
oligometastatic state, whereas two groups did not specify any
limitations.
Eight of 13 institutions reported the use of a stereotactic
body frame or immobilizing cradle (Table 4). Six of these
groups and one other group used abdominal compression to
reduce tumor excursion during the respiratory cycle. All insti-
tutions reported techniques used to manage tumor motion at
simulation or at treatment delivery. The use of a body frame and
soft-tissue pretreatment verification (through CT) has been
shown to be a rigorous and reproducible method of reducing
setup error.25,39 Dose fractionation varied from 33 Gy/6 fractions
up to 60 Gy/3 fractions, with treatment delivery time varying
greatly between institutions. Beam arrangement ranged from 3
to 12 static noncoplanar and coplanar beams, although the use of
photon arc therapy was reported in 5 of 13 groups. Brown
TABLE 2. Lengths of Follow-Up, Outcomes, Toxicities Dose, Organ Constraints, Toxicities, and BED
Group
F/U Period (mo)
Median (Range) Outcomes Single Fraction Dose
Constraints for
Critical Organs Toxicity
BED at
Isocenter
BED at
Periphery
Nakagawa Median 10 (2–82) 95% crude LC, median
survival 9.4 mo
estimated 2-yr o/s
35%, estimated 2-yr
LC 91%
Median 20 Gy (range,
15–25 Gy)
prescribed to
covering isodose
Not specified No grade 3 or
above
Not reported 60 Gy median
Hara Median 13 (3–24) 62% 1-yr LC at 30
Gy, 86% 1-yr LC at
30 Gy, 79% total
crude LC, estimated
2-yr LC 48%
30 Gy (n  8)
30 Gy (n  7)
prescribed to
isocenter
Not specified 9% grade 3 and
18% grade 2
radiation
pneumonitis
Not reported 87.5 Gy
median
Wulf Median 14 (2–37) 100% crude LC and
33% actuarial 2-yr o/s
26 Gy, prescribed to
covering isodose
Mediastinal organs No grade 3 or
above
138 Gy 93.6 Gy
Le Median 18 (9–32)
(pooled with
NSCLC)
67% crude LC at 15–20
Gy, 56% crude LC at
25 Gy, 1-yr o/s 56%,
estimated 2-yr o/s
32%, estimated 2-yr
LC 56.3%
15 Gy–20 Gy (n  3),
25 Gy (n  9),
prescribed to
covering isodose
Mediastinal organs
and lungs
19% pneumothorax
with fiducial
insertion (pooled
with NSCLC)
73% patients
received
100 Gy
62% patients
received
50 Gy
Fritz Median 22 mo
(6.8–83 mo)
87% crude LC, 73%
2-yr o/s
30 Gy prescribed to
isocenter
Mediastinal organs 73% radiological
pneumonitis
120 Gy 100 Gy
Hof Median 14 (1.5–82) 65.1% 2-yr o/s, 47.8%
3-yr o/s, 73.7% 2-yr
LC, 63.1% 3-yr LC
24 Gy (n  28),
26 Gy (n  20),
other doses (n 
23) all prescribed to
isocenter
Mediastinal organs
and lungs
5% grade 3
pneumonitis
Variable Not reported
BED, biological equivalent doses; NSCLC, non-small cell lung cancer.
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reported results with the use of a CyberKnife, whereas all other
groups used a gantry operated linear accelerator.
The median follow-up period reported among the 13
institutions ranged between 8.2 and 44 months (median of 18.2
months follow-up). Local control varied widely from 67% crude
to 96% at 2 years (Table 5). Weighted 2-year local control was
77.9%. Overall survival varied widely among institutions, re-
flecting variation patient characteristics rather than in treatment
techniques. Weighted 2-year overall survival was 53.7% (range,
33–89%). Three institutions reported local control and overall
survival results pooled with a similarly treated NSCLC cohort;
these are noted below. Among the institutions reported, toxicity
was very low. This is likely to reflect the retrospective nature of
the majority of reports and incomplete toxicity recording. The
weighted rate of grade 3 or greater toxicity was 2.6%. There was
a grade 5 esophageal necrosis reported in one patient treated to
TABLE 3. Reference(s), Patient/Target Population, and Tumor Characteristics
Author(s)
Patients/
Targets
Target Size Median
(Range)
Eligible
Locations
Number of
Synchronous
Metastases Phase I Data? Primary/Histology (%)
Lax et al. and Blomgren
et al.22,23
13/17 Volume 48 ml
(3–198 ml)
Central/peripheral Not specified No Not reported
Uematsu et al.24 29/43 4 cm Central/peripheral Not specified No 35% colorectal, 26% lung,
17% breast, 7% kidney,
7% sarcoma, 7% others
Nagata et al.25 9/9 Not reported Central/peripheral 1 to 2 No 44% colon, 22% H & N,
11% lung, 11% liver,
11% sarcoma
Onimaru et al.26 20/32 6.0 cm median 2.5 cm
(0.6–6.0 cm)
Central/peripheral 1 only Yes, at affiliated
hospital
45% renal, 22% lung, 6%
bladder, 6% breast, 6%
H & N, 3% liver, 3%
rectal, 3% melanoma,
3% thymic, 3% thyroid
Wulf et al.18,27,28 25/51 17 ml (1–155 ml) Peripheral only 1 to 2 No 45% NSCLC, 10% breast,
8% colon, 8% kidney,
8% sarcoma, 6% liver,
4% thyroid, 8% others
Song et al.29 13/20 Range, 1–5.5 cm Central/peripheral 1 to 2 No 15% sarcoma, 15% H & N,
15% kidney, 8% breast,
8% lung, 8% esophagus,
8% uterine, 8% ovarian,
8% colon, 8% testes
Min Yoon et al.30 53/80 PTV  43.9 ml
(4.3–213 ml)
Central/peripheral 1 to 3 Yes 28% lung, 22% liver, 19%
colorectal, 11% H & N,
8% esophagus, 4%
uterine, 2% gastric, 2%
anal, 2% breast, 2%
sarcoma
Aoki et al.31 8 targets 50 mm mean  11.8
ml (3–44 ml)
Central/peripheral 1 to 3 No 62% lung, 13% liver, 13%
esophagus, 13% H & N
Milano et al. and
Okunieff et al.32–34
50/125 2.1 cm median (0.3–7.7
cm) volume median
4.7 (0.1–125 ml)
Central/peripheral 1 to 5 No 29% CRC, 20% breast,
16% lung, 35% other
Norihisa et al.35 34/43 40% 15 mm, 51%
15–30 mm, 9%
30–40 mm
Central/peripheral 1 to 2 No 65% AdenoCa, 15%
SCC, 9% RCC, 6%
adenoid cystic, 3%
pleomorphic
carcinoma, 3%
osteosarcoma
Brown et al.36 35/69 5.0 cm range,
0.7–152 ml
Central/peripheral 1 to 3 No 22% lung, 18% kidney, 15%
sarcoma, 10% H & N, 6%
urothelial, 6% testicular,
4% colorectal, 10% others
Salazar et al.37 7 targets 124 ml (pooled with
NSCLC)
Central/peripheral 1 to 2 No 28% lung, 28% CRC, 14%
breast, 14% H & N, 14%
tongue
Rusthoven et al.38 38/63 lesions Targets 5 cm, median
4.2 ml (0.2–52.3 ml)
Peripheral only 1 to 3 Yes 24% colorectal, 18%
sarcoma, 18% kidney,
13% lung, 8%
melanoma, 8% H & N,
5% breast, 5% other
NSCLC, non-small cell lung cancer; PTV, planning target volume; CRC, colorectal carcinoma; SCC, squamous cell carcinoma; RCC, renal cell carcinoma.
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48 Gy/4 fx to a central target. The BED in 2 Gy fractions using
an / ratio of 10 were reported 10 of 13 groups, and a BED in
2 Gy fractions using an / ratio of 20 was reported in one
group.
DISCUSSION
The wide variety of treatment techniques and dose
fractionation schemes reported in the literature indicates that
there is, as yet, no consensus as to a standard approach for the
stereotactic radiotherapy of pulmonary metastases. The ex-
isting literature indicates that high levels of local control are
achievable, but in the absence of randomized trials, the effect
on survival is unknown. In the stereotactic NSCLC experi-
ence, Onishi et al.40 retrospectively analyzed 245 patients and
found that a prescription of BED 100 Gy at the isocenter
predicted for local control (8.1% local failures versus 26.4%
in targets receiving BED 100 Gy [p  0.01]). Wulf et al.18
concluded that the tumor control probability of 50% occurred
at a BED of 94 Gy at the isocenter, and 50 Gy at the PTV
margin, with a steep increase at higher doses. He concluded
that some fractionation schemes (such as 54 Gy in three
fractions41 used for NSCLC in RTOG-0236) have a BED
150 Gy at the isocenter and are biologically in the plateau
beyond the 90% tumor control probability and supralethal.
Among the institutions reviewed using single fraction ra-
dioablation, Fritz et al.19 and Wulf et al. prescribed doses
closest to approximating these figures. Together, a total
of 56 targets were treated with a reported 2-year local control
of 93%.
TABLE 4. Radiotherapy Treatment Delivery; Immobilization, Margin Determination, Motion Management, Fractionation,
Treatment Delivery Time and, Beam Arrangement
Study Group Motion Management Fractionation
Treatment Delivery
Time Beam Arrangement
Lax, Blomgren Standard planning CT, stereotactic body
frame
21–66 Gy in 1–3 fx prescribed
to 66% isodose
Not specified 4–8 coplanar beams 6
or 21 MV
Uematsu Planning and pretreatment slow-CT  x-ray,
abdominal compression
33/6/1 to 76/8/6 prescribed to
the 80% isodose
Variable Not specified
Nagata Planning CT  x-ray, pretreatment
orthogonal x-rays, stereotactic body
frame  abdominal compression
48 Gy in 4 fx, prescribed to
isocenter
Over 5–13 d
(median 12)
6–10 noncoplanar static
or up to 7 arcs of
6 MV
Onimaru Planning CT in three phases; kilovoltage
imaging pretreatment
48 Gy/8 fx, n  22 for central
targets or 3.0 cm, 60 Gy/8
fx, n  10 for peripheral
targets prescribed to
isocenter
8 fx delivered over
2 wk
4–12 static beams or
3–4 arcs
Wulf Planning 4DCT, pretreatment CT,
Stereotactic body frame
3  10 Gy n  12, 3  12–
12.5 Gy n  14, prescribed
to covering isodose
48–72 h fraction
interval
5–9 static/arc fields
Song Custom frame and stereotaxis with 6–7
infrared markers, pretreatment CT 
orthogonal x-ray
median dose 35 Gy (27–45
Gy) maximum daily dose
15 Gy
3 consecutive days 4–8 coplanar beams or
arcs
Yoon Planning fluoroscopy  CT, pretreatment CT,
stereotactic body frame  abdominal
compression
30 Gy/3 fx, 19.8% patients 40
Gy/4 fx, 44% patients 48
Gy/4 fx, 36.7% patients
(sample pooled with
NSCLC), 90% isodose
covering PTV margin
Consecutive days 3–8 coplanar and
noncoplanar beams
(median 5)
Aoki Planning fluoroscopy  CT simulation,
thermo shell and headrest
54 Gy/9 fx prescribed to
isocenter
15 d median (11–22 d) 4–6 10 MV
noncoplanar beams
Milano, Okunieff Respiratory gating with orthogonal
kilovoltage x-rays. Vacuum immobilization
50 Gy/10 fx (n  31), 48 Gy/
6 fx to 57 Gy/3 fx (n 
18), 80% isodose covering
PTV
2 wk, preference for
daily treatment
Not specified
Norihisa Planning CT simulation, x-ray fluoroscopy,
stereotactic body frame  abdominal
compression
48 Gy/4 fx (n  17), 60 Gy/5
fx (n  16) prescribed to
isocenter
4–18 d, median 12 5–7 noncoplanar 6MV
Brown X-ray and optical tracking of fiducials,
stereotactic body frame or vacuum
pillow  abdominal compression
5 Gy-60 Gy delivered in 1–4
fx prescribed to 60–85%
isodose line
Not specified Up to 150 beamlets,
typically 64 beamlets
Salazar Planning fluoroscopy CT, stereotactic body
frame  abdominal compression
Median dose 40 Gy/4 fx Once weekly, 4 wk Median of 5 fields
Rusthoven “Slow” planning CT, pretreatment CT, or
external fiducials, vacuum bag or cradle
immobilization,  abdominal compression
60 Gy/3 fx, prescribed to
covering isodose
Not specified Dynamic arcs or
multiple noncoplanar
beams
CT, computed tomography; NSCLC, non-small cell lung cancer; 4DCT, 4-dimensional CT.
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The influence of tumor volume on local control
remains unclear. There is no clear correlation between
large tumors and propensity for treatment failure. How-
ever, there may be some relationship between fractionation
of radiotherapy and increased probability of tumor control
in larger tumors. On analysis of German radiosurgical and
hypofractionated data, Hof et al.20 postulated that “hypo-
fractionated radiotherapy is superior to single dose therapy
in larger tumor volumes, where the effects of reoxygen-
ation and redistribution gain importance,” with the proviso
that “patient numbers are much too small to date to provide
sufficient reliability on the issue.”
TABLE 5. Treatment Results: Follow Up, Outcomes, Toxicity, and BED
Study Group
F/U Period
Median
(Range) Outcomes Toxicity
BED at
Isocenter BED at Margin
Lax, Blomgren Median 8.2 mo
(3.5–25)
94% crude control. Crude
o/s 46%, mean survival
11.3 mo, estimated 2-yr
LC  83%
Not reported Median 183 Gy Median 112.5 Gy
Uematsu Median 11 mo
(3–31)
97% LC at 11 mo (data
pooled with NSCLC
cohort). Estimated 2-yr
LC  93.6%
Not reported Range, 144–188
Gy
Not reported
Nagata Median 19 mo
(pooled with
NSCLC)
67% crude local control Pooled with NSCLC: only
mild grade 1. No grade 3
or 4
105.6 Gy Not reported
Onimaru Median 18 mo
(2–44)
48% 2-yr o/s, 69.6% 3-yr
pooled LC for 48 Gy (n 
39), 100% 3-yr pooled LC
for 60 Gy (n  19)
One grade 5 esophageal
necrosis in one patient,
one other grade 2 chest
pain, nil else
48 Gy/8  76.8
Gy early 60
Gy/8  105
Gy early
Not reported
Wulf 3  10 Gy
median
17 mo
71% 2-yr LC at 3  10 Gy Overall pneumonitis 3% 3  10 Gy:
BED  117.2
Gy
3  10 Gy: BED 
60 Gy
3  12.5 Gy
median
13 mo
92% 2-yr LC at 3  12.5
Gy o/s for both groups; 1
yr  85%, 2 yr  33%
3  12–12.5 Gy:
BED  168.6
3  12–12.5 Gy:
BED  84.4 Gy
Song Median 14 mo
(9–49),
mean F/U
22.6 mo
90% crude local control,
estimated 2 yr LC 87%
29% grade 1–2 toxicities (4
of 14 patients), 8% hilar
fibrosis  collapse (1 of
14 patients), nil grade 3
or 4
Not reported Not reported
Yoon Median 14 mo
(4–46)
70% LC at 30 Gy/3 fx, 77%
LC at 40 Gy/4 fx
No pulmonary toxicity 2
reported in all groups
Not reported Overall mean  58.6–
118.8 Gy
Median 10 mo
for 48/4
group
100% LC at 48 Gy/4 all
groups pooled 2-yr o/s 
51%
Not reported Mean for 48 Gy/4 fx 
92.7–118.8 Gy
Aoki Median 17.7
mo (9.4–
39.5)
95% crude LC (pooled with
NSCLC), o/s at 2 yr
89.5%, estimated 2-yr
LC  93%
Nil grade 3 or 4 toxicities 86.4 Gy Not reported
Milano, Okunieff Median 18.7
mo (3.7–
60.9)
3-yr actuarial LC
91.0  13.2%, crude
LC  94%, estimated 2-yr
LC  92%, 2-yr o/s 50%
3/49 (6%) grade 2, 1/49
(2%) grade 3 pericardial
effusion
Not reported Minimum 56 Gy at PTV
margin
Norihisa Median 27 mo
(10–80)
2-yr LC 90%. 2-yr o/s 84% 1/34 grade 3 toxicity, 6%
(2/34) musculoskeletal,
grade 2 pneumonitis in
12% (4/34)
132 Gy Not reported
Brown Median 18 mo
(2–41)
77% crude o/s. Estimated
2-yr o/s  72.5%, LC not
reported, 84% response
rate
One patient with grade 4
pneumonitis
6–110 Gy using
/ ratio of 20
Variable
Salazar Median 44 mo
(2–84)
86% crude LC, median
o/s  19 mo, 3-yr o/s
29%
Pooled toxicity with
NSCLC: 19% overall,
7% grade 2, no grade 3
or 4
119.6 Gy Not reported
Rusthoven Median 15.4
mo (6–48)
2-yr LC 96%, 2-yr o/s 39% 10.5% grade 2, 7.9% grade
3, zero grade 4
Not reported 180 Gy
BED, biological equivalent doses; NSCLC, non-small cell lung cancer.
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It is difficult to compare overall survival data with the
historical surgical series. Most patients that were reported in
these publications were medically inoperable with multiple
medical comorbidities and competing risks for survival. The
four largest series of stereotactic fractionated radiotherapy
(Min Yoon et al.,30 Milano et al.,32,34 Rusthoven et al.,38 and
Norihisa et al.35) prescribed BEDs 100 Gy at the isocenter
and/or the periphery of the targets. A total of 311 targets
among 175 patients were treated with an overall crude local
control rate of 91%. The 2-year weighted overall survival was
54.5%. By comparison, the 2-year overall survival rate in the
International Registry of Lung metastases for completely
resected metastases was 70%.35 These figures suggest that
impressive longevity can occur in carefully selected patients
with locally confined metastatic pulmonary disease.
Reported toxicities were minimal between the institu-
tions. There was a 2.6% rate (4 of 154) of grade 3 or higher
toxicities in the radioablative series, and a 4% rate (9 of 224)
of grade 3 or higher toxicities in the radiotherapy series.
There was a low rate of grade 1 and grade 2 toxicities
reported, which may reflect incomplete reporting associated
with the retrospective design of the majority of these studies.
There was a patient death due to esophageal necrosis related
directly to fractionated radiotherapy of a centrally located
target. Timmerman et al.21 have reported higher incidence of
grades 3 to 5 toxicities when treating targets 2 cm distance
from the mediastinal envelope and the lobar bronchi with a
dose of 54 Gy in three fractions (heterogeneity corrected41).
This concurs with the Stanford University CyberKnife11 ra-
dioablative data reported here, where three of the eight
patients suffering major toxicities had centrally located tu-
mors. Chemotherapy may exacerbate toxicity; Le et al.11
reported two deaths when gemcitabine chemotherapy was
used shortly after stereotactic radiotherapy, suggesting a
potential radiation recall reaction. Evidence suggests increas-
ing tumor volume is associated with increased toxicity. Mc-
Garry et al.42 reported increased incidence of grade 3 and
above toxicities when treating target diameters of 5 cm in
a phase I dose escalation study. In this review, most institu-
tions have either excluded or reduced the dose to centrally
located tumors, and excluded very large tumors. Unfortu-
nately, there has been scant long-term toxicity data collected
for stereotactic hypofractionated therapy in the lungs. Pulmo-
nary fibrosis is a well-known late effect associated with larger
doses per fraction. The lack of a reported link between the
number of treated metastases and subsequent toxicity is
counter intuitive and be reflective of the short reported
follow-up. As stereotactic techniques and survival improve,
we are likely to encounter increasing issues with late toxici-
ties many months to years after initial therapy.
Difficulties in assessment of tumor response were not
specifically addressed in the publications reviewed. Large
doses per fraction used in SBRT may cause segmental atel-
ectasis or focal fibrosis,43 which can confound response
assessment with conventional CT. There is scant data to
address optimal tumor response assessment in stereotactic
radiotherapy for oligometastatic disease. In the setting of
SBRT for NSCLC, Timmerman et al.21 reported that 17 of 70
patients had increased opacity on CT suspicious of recur-
rence. Despite this, only three of these 17 patients had biopsy
confirmed recurrence. Similarly, Takeda et al.44 reported 20
of 50 patients treated with pulmonary SBRT with radiologic
findings suspicious for recurrence, subsequently confirmed in
only three cases. The role of 18F-fluorodeoxyglucose positron
emission tomography in response assessment is still unclear.
Evidence is limited, but it may be that normal tissue inflamma-
tion may confound metabolic response assessment. Henderson
et al.45 reported that more than half of the 14 patients treated
with pulmonary SBRT maintained a moderately elevated met-
abolic activity on 18F-fluorodeoxyglucose positron emission
tomography scanning, despite no patient failing locally with a
median follow-up of 42 months.
The importance of tumor localization and motion man-
agement in the delivery of hypofractionated radiotherapy is
paramount. It appears that it is equally important to have
onboard imaging capable of volumetric soft tissue definition,
without the need for patient transfer to the treatment position.
Recently, Guckenberger et al.46 reported experience using
pretreatment on-board CT with a stereotactic body frame.
The discrepancy between actual versus planned tumor posi-
tion was 7.7  1.3 mm, with poor correlation between tumor
position and bony landmarks. Pretreatment CT should ideally
be complemented with four-dimensional CT scanning in the
planning phase to determine maximal tumor excursion. By
minimizing setup uncertainty, a highly conformal dose can be
delivered.
No inferences can be made from this data about
ideal beam arrangements, number of beams, or beam
energies used.
Quality of life is an issue that issue that is yet to be
addressed. As yet, there has been no data published in the
hypofractionated treatment of lung oligometastases using
internationally validated quality of life measurement tools. In
its current form, stereotactic hypofractionated radiotherapy is
still in its infancy as an experimental treatment for oligome-
tastases of the lung. At this point, a recommendation cannot
be made for a fractionation scheme, which suggests the need
for further prospective investigations. The most promising
results seem to be from prescribing a BED of 100 Gy at the
isocenter and a BED approximating 100 Gy at the tumor
periphery. Comparisons with surgical data are difficult in the
absence of randomized phase II data comparing metastasec-
tomy with stereotactic radiotherapy. Once, a more robust
dataset is collated for any of the described techniques and
fractionation schemes, perhaps stereotactic radiotherapy may
be considered a noninvasive alternative to surgery for the
treatment of oligometastatic pulmonary disease.
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